Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash & Equivalents for 7 consecutive years, with $48.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 74.11% to $48.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $48.6 million, a 74.11% decrease, with the full-year FY2024 number at $149.3 million, down 40.05% from a year prior.
  • Cash & Equivalents was $48.6 million for Q3 2025 at 4D Molecular Therapeutics, down from $77.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $275.7 million in Q3 2023 to a low of $48.6 million in Q3 2025.
  • A 5-year average of $157.8 million and a median of $149.3 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 375.84% in 2023, then crashed 74.11% in 2025.
  • 4D Molecular Therapeutics' Cash & Equivalents stood at $153.0 million in 2021, then crashed by 65.78% to $52.4 million in 2022, then skyrocketed by 375.84% to $249.1 million in 2023, then tumbled by 40.05% to $149.3 million in 2024, then tumbled by 67.49% to $48.6 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Cash & Equivalents are $48.6 million (Q3 2025), $77.2 million (Q2 2025), and $133.5 million (Q1 2025).